FE 203799

Drug Profile

FE 203799

Alternative Names: FE-203799; Glucagon-like peptide-2 receptor agonist - Ferring Pharmaceuticals/GLyPharma

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ferring Pharmaceuticals
  • Developer GLyPharma Therapeutic
  • Class
  • Mechanism of Action Glucagon-like peptide 2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastrointestinal disorders

Most Recent Events

  • 31 Jan 2018 GLyPharma Therapeutic plans a phase I/II trial for Lymphomas in April 2018 , (NCT03417765)
  • 23 Jan 2018 GLyPharma Therapeutic plans a phase Ib/IIa trial for Gastrointestinal disorders in February 2018 (NCT03408132)
  • 18 Jan 2018 Phase-II clinical trials in Gastrointestinal disorders in Denmark (SC, Injection) (EudraCT2017-002486-21)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top